368 related articles for article (PubMed ID: 26827824)
1. Oxidative stress and proteasome inhibitors in multiple myeloma.
Lipchick BC; Fink EE; Nikiforov MA
Pharmacol Res; 2016 Mar; 105():210-5. PubMed ID: 26827824
[TBL] [Abstract][Full Text] [Related]
2. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
3. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
4. [Proteasome inhibitors in treatment of multiple myeloma].
Kubiczková L; Matějíková J; Sedlaříková L; Kryukov F; Hájek R; Sevčíková S
Klin Onkol; 2013; 26(1):11-8. PubMed ID: 23528167
[TBL] [Abstract][Full Text] [Related]
5. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Dolloff NG
Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells.
Fink EE; Mannava S; Bagati A; Bianchi-Smiraglia A; Nair JR; Moparthy K; Lipchick BC; Drokov M; Utley A; Ross J; Mendeleeva LP; Savchenko VG; Lee KP; Nikiforov MA
Leukemia; 2016 Jan; 30(1):104-11. PubMed ID: 26205085
[TBL] [Abstract][Full Text] [Related]
7. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
[TBL] [Abstract][Full Text] [Related]
8. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A
Expert Opin Investig Drugs; 2014 Sep; 23(9):1193-209. PubMed ID: 24905450
[TBL] [Abstract][Full Text] [Related]
9. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition in multiple myeloma: lessons for other cancers.
Saavedra-García P; Martini F; Auner HW
Am J Physiol Cell Physiol; 2020 Mar; 318(3):C451-C462. PubMed ID: 31875696
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase-1 in multiple myeloma.
Abe K; Ikeda S; Nara M; Kitadate A; Tagawa H; Takahashi N
Cancer Med; 2023 Apr; 12(8):9709-9722. PubMed ID: 36775962
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
15. [Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma].
Wang YR; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1584-1587. PubMed ID: 37846721
[TBL] [Abstract][Full Text] [Related]
16. Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.
Cao MN; Zhou YB; Gao AH; Cao JY; Gao LX; Sheng L; Xu L; Su MB; Cao XC; Han MM; Wang MK; Li J
Biochim Biophys Acta; 2014 Jun; 1840(6):2004-13. PubMed ID: 24534329
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor therapy in multiple myeloma.
Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
[TBL] [Abstract][Full Text] [Related]
18. Novel targeted therapies and combinations for the treatment of multiple myeloma.
Agarwal A; Mahadevan D
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):2-15. PubMed ID: 22882073
[TBL] [Abstract][Full Text] [Related]
19. Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.
Zafeiropoulou K; Kalampounias G; Alexis S; Anastasopoulos D; Symeonidis A; Katsoris P
PLoS One; 2024; 19(2):e0289904. PubMed ID: 38412186
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
Feng R; Oton A; Mapara MY; Anderson G; Belani C; Lentzsch S
Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
